{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:36:16Z","timestamp":1786988176574,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejso.2025.110424","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T06:38:17Z","timestamp":1756795097000},"page":"110424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized control trials"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8898-4187","authenticated-orcid":false,"given":"Gabriela Branquinho","family":"Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4128-9376","authenticated-orcid":false,"given":"Camila Mariana","family":"de Paiva Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fanior Samuel Alonso","family":"de Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Val\u00e9rio-Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"de Melo Sprogis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela Anderson","family":"Colares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9722-8519","authenticated-orcid":false,"given":"Rafael","family":"Morriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejso.2025.110424_bib1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110424_bib2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"10177","key":"10.1016\/j.ejso.2025.110424_bib3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejso.2025.110424_bib4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib5","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.110424_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2025.110424_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"issue":"9","key":"10.1016\/j.ejso.2025.110424_bib9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN guidelines\u00ae insights: ovarian cancer, version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"3","key":"10.1016\/j.ejso.2025.110424_bib10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3747\/co.27.6033","article-title":"Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline","volume":"27","author":"Auer","year":"2020","journal-title":"Curr Oncol Tor Ont"},{"issue":"5","key":"10.1016\/j.ejso.2025.110424_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ejso.2025.110424_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13020258","article-title":"Effectiveness of hyperthermic intraperitoneal chemotherapy associated with cytoreductive surgery in the treatment of advanced ovarian cancer: systematic review and meta-analysis","volume":"13","author":"Llueca","year":"2023","journal-title":"J Personalized Med"},{"key":"10.1016\/j.ejso.2025.110424_bib13","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1245\/s10434-025-16979-6","article-title":"Cytoreductive surgery plus HIPEC in recurrent or newly diagnosed advanced epithelial ovarian cancer: a meta-analysis","volume":"32","author":"Taliento","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib14","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2025.110424_bib15","series-title":"Cochrane handbook for systematic reviews of 364 interventions","author":"Higgins","year":"2019"},{"issue":"1","key":"10.1016\/j.ejso.2025.110424_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.ejso.2025.110424_bib17","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2025.110424_bib18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ejso.2025.110424_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejso.2025.110424_bib20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib21","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ygyno.2018.04.079","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer: preliminary results of a phase II randomized clinical trial","volume":"149","author":"Diaz-Montes","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13048-024-01468-3","article-title":"The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial)","volume":"17","author":"Wang","year":"2024","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejso.2025.110424_bib24","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.24.00686","article-title":"Hyperthermic intraperitoneal chemotherapy in platinum-sensitive recurrent ovarian cancer: a randomized trial on survival evaluation (HORSE; MITO-18)","volume":"43","author":"Fagotti","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib26","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110424_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study","volume":"26","author":"Winter","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110424_bib28","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IGC.0b013e31824d836c","article-title":"Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer","volume":"22","author":"Ansaloni","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2025.110424_bib29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","article-title":"Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma","volume":"33","author":"Lemoine","year":"2017","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"issue":"3","key":"10.1016\/j.ejso.2025.110424_bib30","first-page":"139","article-title":"Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study","volume":"46","author":"Muller","year":"2011","journal-title":"Eur Surg Res Eur Chir Forsch Rech Chir Eur"},{"key":"10.1016\/j.ejso.2025.110424_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110907","article-title":"Paclitaxel increases sensitivity of SKOV3 cells to hyperthermia by inhibiting heat shock protein 27","volume":"132","author":"Kong","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejso.2025.110424_bib32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/curroncol31020048","article-title":"Paclitaxel as HIPEC-drug after surgical cytoreduction for ovarian peritoneal metastases: a randomized phase III clinical trial (HIPECOVA)","volume":"31","author":"Villarejo Campos","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib33","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2019.30.e3","article-title":"Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study","volume":"30","author":"Lee","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ejso.2025.110424_bib34","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejso.2025.110424_bib35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2025.110424_bib36","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325008522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325008522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:21:57Z","timestamp":1761963717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325008522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0748798325008522"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110424","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized control trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110424"}}